MEXICO CITY, Oct. 24 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products Company, announced today its results for the third quarter and nine month periods ended September 30, 2008. All figures included herein were prepared in accordance with Mexican GAAP; 2008 figures are stated in nominal Mexican pesos and 2007 figures have been restated in constant Mexican pesos as of December 31, 2007.
3Q08 Highlights (vs. 3Q07) -- Net sales reached Ps. 712.4 million, an increase of 42.9%. -- Gross profit was Ps. 538.2 million, an increase of 45.3%. -- EBITDA(1) increased 40.2% to Ps. 201.8 million. -- Consolidated net income rose 32.4% to Ps. 150.7 million. -- Earnings per share(2) increased 109.8% to Ps. 0.80. -- During the third quarter, we successfully launched eight products under five existing brands (Base Brands(3) and Prior Year Launches(4)) as part of our line extension strategy. -- We also launched four products under two New Brands(5), as part of our new products launch plan during the third quarter.
For the complete version of this earnings report, please visit: http://www.genommalab.com/ .
(1) EBITDA is defined as earnings before interest, taxes, depreciation and amortization. (2) Earnings per share is for the last 12 months. Earnings per share were calculated using the weighted average of shares outstanding for the period. (3) As defined below. (4) As defined below. (5) As defined below.
